BAYER yesterday announced
the availability of Petibelle
(ethinyloestradiol 30mcg/
drospirenone 3mg), a “new and
further brand in the Yasmin family”
of oral contraceptives.
Bayer said it was introducing the
new brand to provide a further
choice of contraception, while the
original Yasmin brand also remains.
As with Yasmin, Petibelle is
available as a private prescription in
1 x 28 tabs and 3 x 28 tab packs.
The release follows Bayer’s recent
court win against Generic Health/
Lupin Australia and Apotex (TD 23
Jun) in which their appeal against
a former decision about patent
infringement was dismissed.
Generic Health cannot resume
supply of Isabelle in Australia
until Feb 2023, and Bayer can also
recover monetary compensation
from Generic Health and Lupin.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jul 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.